Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610 Pres...
23 Novembre 2020 - 7:00PM
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a
clinical-stage biopharmaceutical company using its expertise in
epigenetics to discover and develop novel therapeutics, will host a
virtual analyst/investor event and conference call on December
7 at 8:00 AM EDT to discuss the data from two oral
presentations and two posters on the MANIFEST clinical trial for
CPI-0610 being presented at the 62nd American Society of
Hematology (ASH) Annual Meeting and Exposition.
The event will include:
- a review of the
clinical and translational data from MANIFEST presented during ASH,
including 24-week data from 50 – 60 first-line and 90 –100
second-line myelofibrosis patients, and
- a physician panel discussion and
question-and-answer session with Dr. John Mascarenhas,
Associate Professor of Medicine at the Icahn School of Medicine at
Mount Sinai- New York and Dr. Serge Verstovsek, Professor
of Medicine at University of Texas MD Anderson Cancer
Center.
This event will be webcast live and can be accessed on the
Investor Relations section of Constellation’s website
at http://ir.constellationpharma.com/events-and-presentations/events.
To participate in the live question-and-answer session, please dial
(877) 473-2077 (domestic) or (661) 378-9662 (international) and
refer to conference ID 7164095.
About MANIFEST
MANIFEST is an open-label Phase 2 clinical trial of CPI-0610 in
patients with myelofibrosis (MF), a rare cancer of the bone marrow
that disrupts the body’s normal production of blood cells.
Constellation is evaluating CPI-0610 in combination with
ruxolitinib in JAK-inhibitor-naïve MF patients (Arm 3), with a
primary endpoint of the proportion of patients with a ≥35% spleen
volume reduction from baseline (SVR35) after 24 weeks of treatment.
Constellation is also evaluating CPI-0610, either as a monotherapy
in patients who are resistant to, intolerant of, or ineligible for
ruxolitinib and no longer on the drug (Arm 1), or as add-on therapy
in combination with ruxolitinib in patients with a sub-optimal
response to ruxolitinib or MF progression (Arm 2). Patients in Arms
1 and 2 are being stratified based on Transfusion Dependence (TD)
status. The primary endpoint for the patients in cohorts 1A and 2A,
who were TD at baseline, is conversion to Transfusion Independence
for 12 consecutive weeks. The primary endpoint for the patients in
cohorts 1B and 2B, who were not TD at baseline, is the proportion
of patients with a ≥35% spleen volume reduction from baseline after
24 weeks of treatment.
About Constellation
PharmaceuticalsConstellation Pharmaceuticals is a
clinical-stage biopharmaceutical company developing novel
therapeutics that selectively modulate gene expression to address
serious unmet medical needs in patients with cancer. The
Company has a deep understanding of how epigenetic and chromatin
modifications in cancer cells and in the tumor and immune
microenvironment play a fundamental role in driving disease
progression and drug resistance. Constellation is driving
development of the BET inhibitor CPI-0610 for the
treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209
for the treatment of solid tumors. The Company is also
applying its broad research and development capabilities to explore
other novel targets that directly and indirectly impact gene
expression to fuel a sustainable pipeline of innovative
small-molecule product candidates.
Contacts
Kia Khaleghpour, PhDVice President, Investor Relations and
CommunicationsConstellation Pharmaceuticals+1
617-844-6859kia.khaleghpour@constellationpharma.com
Lauren ArnoldMedia RelationsMacDougall Biomedical
Communications+1 781-235-3060larnold@macbiocom.com
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Constellation Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur